Cytokine and nitric oxide patterns in dogs immunized with LBSap vaccine, before and after experimental challenge with Leishmania chagasi plus saliva of Lutzomyia longipalpis

Veterinary Parasitology

Volumn 198, Issue 3-4, 2013, Pages 371-381

  Resende, Lucilene Aparecida ^a,b   Roatt, Bruno Mendes ^a   Aguiar Soares, Rodrigo Dian de Oliveira ^a   Viana, Kelvinson Fernandes ^b   Mendonça, Ludmila Zanandreis ^a,b   Lanna, Mariana Ferreira ^a,b   Silveira Lemos, Denise ^b   Corrêa Oliveira, Rodrigo ^c   Martins Filho, Olindo Assis ^c   Fujiwara, Ricardo Toshio ^b   Carneiro, Cláudia Martins ^a   Reis, Alexandre Barbosa ^a,c   Giunchetti, Rodolfo Cordeiro ^a,b,c  

^a FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Canine visceral leishmaniasis; Cytokines; Immunoprotection; Leishmania chagasi; Vaccine

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; NITRIC OXIDE; SAPONIN; TRANSFORMING GROWTH FACTOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOG; FEMALE; IMMUNE RESPONSE; INTERFERON PRODUCTION; LEISHMANIA BRAZILIENSIS; LEISHMANIA CHAGASI; LUTZOMYIA LONGIPALPIS; MALE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROMASTIGOTE; VACCINATION; VISCERAL LEISHMANIASIS;

CANIS FAMILIARIS; LEISHMANIA BRAZILIENSIS; LEISHMANIA DONOVANI CHAGASI; LUTZOMYIA LONGIPALPIS;

CANINE VISCERAL LEISHMANIASIS; CYTOKINES; IMMUNOPROTECTION; LEISHMANIA CHAGASI; VACCINE;

ANIMALS; ANTIGENS, PROTOZOAN; BONE MARROW; CYTOKINES; DOG DISEASES; DOGS; FEMALE; LEISHMANIA; LEISHMANIASIS; LEISHMANIASIS VACCINES; LEUKOCYTES, MONONUCLEAR; MALE; NITRIC OXIDE; SALIVA; VACCINATION;

EID: 84888428212     PISSN: 03044017     EISSN: 18732550     Source Type: Journal    
DOI: 10.1016/j.vetpar.2013.09.011     Document Type: Article

References (63)

1. Alves C.F., De Amorim I.F., Moura E.P., Ribeiro R.R., Alves C.F., Michalick M.S., Kalapothakis E., Bruna-Romero O., Tafuri W.L., Teixeira M.M., Melo M.N. Expression of IFN-gamma, TNF-alpha IL-10 and TGF-beta in lymph nodes associates with parasite load and clinical form of disease in dogs naturally infected with Leishmania (Leishmania) chagasi. Vet. Immunol. Immunopathol. 2009, 128:349-358.
2. Andrade H.M., Toledo V.P.C.P., Mayrink W., Genaro O. Evaluation of the immune response and production of interferon in canine visceral leishmaniasis. Rev. Med. Vet. 1999, 50:809-814.
3. Araújo M.S., de Andrade R.A., Vianna L.R., Mayrink W., Reis A.B., Sathler-Avelar R., Teixeira-Carvalho A., Andrade M.C., Mello M.N., Martins-Filho O.A. Despite Leishvaccine and Leishmune trigger distinct immune profiles, their ability to activate phagocytes and CD8+ T-cells support their high-quality immunogenic potential against canine visceral leishmaniasis. Vaccine 2008, 26:2211-2224.
4. Araújo M.S., de Andrade R.A., Sathler-Avelar R., Teixeira-Carvalho A., Andrade M.C., Vianna L.R., Mayrink W., Reis A.B., Malaquias L.C.C., Mello M.N., Martins-Filho A.O. T-cell-derived cytokines, nitric oxide production by peripheral blood monocytes and seric anti-Leishmania (Leishmania) chagasi IgG subclass patterns following immunization against canine visceral leishmaniasis using Leishvaccine and Leishmune. Vaccine 2009, 27:1008-1017.
5. Barral A., Barral-Netto M., Yong E.C., Brownell C.E., Twardizik D.R., Reed S.G. Transforming growth factor beta as a virulence mechanism for Leishmania braziliensis. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:3442-3446.
6. Bogdan C. Nitric oxide and the immune response. Nat. Immunol. 2001, 2:907-916.
7. Boggiatto P.M., Ramer-Tait A., Metz K., Kramer E.E., Gibson-Corley K., Mullin K., Hostetter J.M., Gallup J.M., Jones D.E., Petersen C.A. Immunologic indicators of clinical progression during canine Leishmania infantum infection. Clin. Vacc. Immunol. 2010, 17:267-273.
8. Borja-Cabrera G.P., Correia-Pontes N.N., da Silva V.O., Paraguai de Souza E., Santos W.R., Gomes E.M., Luz K.G., Palatnik M., Palatnik de Sousa C.B. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonçalo do AmaranteRN). Vaccine 2002, 20:3277-3284.
9. Brachelente C., Muller N., Doherr M.G., Sattler U., Welle M. Cutaneous Leishmaniasis in naturally infected dogs is associated with a T helper-2- biased immune response. Vet. Pathol. 2005, 42:166-175.
10. Carrillo E., Ahmed S., Goldsmith-Pestana K., Nieto J., Osorio Y., Travic B., Moreno J., McMahon-Pratt D. Immunogenicity of the P-8 amastigote antigen in the experimental model of canine visceral leishmaniasis. Vaccine 2007, 25:1534-1543.
11. Chamizo C., Moreno J., Alvar J. Semi-quantitative analysis of cytokine expression in asymptomatic canine leishmaniasis. Vet. Immunol. Immunopathol. 2005, 103:67-75.
12. Correa A.P., Dossi A.C., Vasconcelos R.O., Munari D.P., De Lima V.M.F. Evaluation of transformation growth factor beta1, interleukin-10, and interferon-gamma in male symptomatic and asymptomatic dogs naturally infected by Leishmania (Leishmania) chagasi. Vet. Parasitol. 2007, 143:267-274.
13. Dantas-Torres F. Leishmune vaccine: the newest tool for prevention and control of canine visceral leishmaniosis and its potential as a transmission-blocking vaccine. Vet. Parasitol. 2006, 141:1-8.
14. De Lima V.M.F., Peiro J.R., Vasconcelos R.O. IL-6 and TNF-α production during active canine visceral leishmaniasis. Vet. Immunol. Immunopathol. 2007, 115:189-193.
15. ® in an endemic area for visceral leishmaniasis. Vet. Immunol. Immunopathol. 2010, 135:296-302.
16. Deane L.M. Reservoirs of Leishmania donovani in Brazil. Rev. Assoc. Med. Bras. 1961, 7:161-169.
17. Degrave W., Fernandes O., Thiemanm O., Wincker P., Britto C., Cardoso A., Pereira J.B., Bozza M., Lopes U., Morel C. Detection of Trypanosoma cruzi and Leishmania using the polymerase chain reaction. Mem. Inst. Oswaldo Cruz 1994, 89:367-368.
18. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp. Immun. Microbiol. Infect. Dis. 2004, 27:305-318.
19. Dye C. The logic of visceral leishmaniasis control. Am. J. Trop. Med. Hyg. 1996, 55:125-130.
20. Fernandes A.P., Costa M.M.S., Coelho E.A.F., Michalickc M.S.M., de Freitas E., Melo M.N., Tafuri W.L., Resende D.M., Hermonte V., Abrantese C.F., Gazzinelli R.T. Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein. Vaccine 2008, 26:5888-5895.
21. Gantt K.R., Schultz-Cherry S., Rodriguez N., Jeronimo S.M.B., Nascimento E.T., Goldman T.L., Recker T.J., Miller M.A., Wilson M.E. Activation of TGF-beta by Leishmania chagasi: importance for parasite survival in macrophages. J. Immunol. 2003, 170:2613-2620.
22. Giunchetti R.C., Correa-Oliveira R., Martins-Filho O.A., Teixeira-Carvalho A., Roatt B.M., Aguiar-Soares R.D.O., Vitoriano-Souza J., Moreira N.D., Malaquias L.C., Castro L.L.M., Lana M., Reis A.B. Immunogenicity of a killed Leishmania vaccine with saponin adjuvant in dogs. Vaccine 2007, 25:7674-7686.
23. Giunchetti R.C., Correa-Oliveira R., Martins-Filho O.A., Teixeira-Carvalho A., Roatt B.M., Aguiar-Soares R.D., Coura-Vital O., Abreu W., Malaquias R.T., Gontijo L.C., Broskyn N.F., Oliveira C., Costa C.I., Lana D.J., Reis M.A.B. A killed Leishmania vaccine with sand fly saliva extract and saponin adjuvant displays immunogenicity in dogs. Vaccine 2008, 26:623-638.
24. Giunchetti R.C., Reis A.B., Silveira-Lemos D., Martins-Filho A.O., Corrêa-Oliveira R., Vale A.M., Quetz J.S., Bueno L.L., França-Silva J.C., Nascimento E., Mayrink W., Fujiwara R.T. Antigenicity of a whole parasite vaccine as promising candidate against canine leishmaniasis. Res. Vet. Sci. 2008, 85:106-112.
25. Gradoni L., Ascenzi P. Nitric oxide and anti-protozoan chemotherapy. Parasitologia 2004, 46:101-103.
26. Green L.C., Wagner D.A., Glogowski J., Skipper P.L., Wishnok J.S., Tannenbaum S.R. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal. Biochem. 1982, 126:131-138.
27. Gutman S.I., Hollywood C.A. Simple, rapid method for determining nitrates and nitrites in biological fluids. Clin. Chem. 1992, 38:2152.
28. Heinzel F.P., Sadick M.D., Holaday B.J., Coffmanj R.L., Locksley R.M. Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J. Exp. Med. 1989, 169:59-72.
29. Holzmuller P., Cavaleyra M., Moreaux J., Kovacic R., Vincendeau P., Papierok G., Lemesre J.L. Lymphocytes of dogs immunised with purified excreted-secreted antigens of Leishmania infantum coincubated with Leishmania infected macrophages produce IFN gamma resulting in nitric oxide-mediated amastigote apoptosis. Vet. Immunol. Immunopathol. 2005, 106:247-257.
30. Hommel M., Jaffe C.L., Travi B., Milon G. Experimental models for leishmaniasis and for testing anti-leishmanial vaccines. Ann. Trop. Med. Parasitol. 1995, 89:55-73.
31. Kane M.M., Mosser D.M. The role of IL-10 in promoting disease progression in leishmaniasis. J. Immunol. 2001, 166:1141-1147.
32. Lage R.S., Oliveira G.C., Busek S.U., Guerra L.L., Giunchetti R.C., Corrêa-Oliveira R., Reis A.B. Analysis of the cytokine profile in spleen cells from dogs naturally infected by Leishmania chagasi. Vet. Immunol. Immunopathol. 2007, 115:135-145.
33. Lemesre J.L., Holzmuller P., Gonçalves R.B., Bourdoiseau G., Hugnet G., Cavaleyra M., Papierok G. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial. Vaccine 2007, 25:4223-4234.
34. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
35. Maia C., Campino L. Cytokine and phenotypic cell profiles of Leishmania infantum infection in the dog. J. Trop. Med. 2012, 7 pp. (Article ID 541571). 10.1155/2012/541571.
36. Manna L., Reale S., Viola E., Vitale F., Foglia Manzillo V., Pavone L.M., Caracappa S., Gravino A.E. Leishmania DNA load and cytokine expression levels in asymptomatic naturally infected dogs. Vet. Parasitol. 2006, 142(3-4):271-280.
37. Manna L., Reale S., Picillo E., Vitale F., Gravino A.E. Interferon-gamma (INF-γ) IL-4 expression levels and Leishmania DNA load as prognostic markers for monitoring response to treatment of leishmaniotic dogs with miltefosine and allopurinol. Cytokine 2008, 44:288-292.
38. Menezes-Souza D., Corrêa-Oliveira R., Guerra-Sá R., Giunchetti R.C., Teixeira-Carvalho A., Martins-Filho A.O., Oliveira G.C., Reis A.B. Cytokine and transcription factor profiles in the skin of dogs naturally infected by Leishmania (Leishmania) chagasi presenting distinct cutaneous parasite density and clinical status. Vet. Parasitol. 2011, 177:39-49.
39. Miralles G.D., Stoeckle M.Y., McDermott D.F., Finkelman F.D., Murray H.W. Induction of Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis. Infect. Immun. 1994, 62:1058-1063.
40. Moreira N.D., Giunchetti R.C., Carneiro C.M., Vitoriano-Souza J., Roatt B.M., Malaquias L.C., Corrêa-Oliveira R., Reis A.B. Histological study of cell migration in the dermis of hamsters after immunisation with two different vaccines against visceral leishmaniasis. Vet. Immunol. Immunopathol. 2009, 128:418-424.
41. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., Coffman R.L. Two types of murine helper T cell clone I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 1986, 136:2348-2357.
42. Murray H.W., Squires K.E., Miralles C.D., Stoeckle M.Y., Granger A.M., Granelli-Piperno A., Bogdan C. Acquired resistance and granuloma formation in experimental visceral leishmaniasis differential T cell and lymphokine roles in initial versus established immunity. J. Immunol. 1992, 148:1858-1863.
43. Murray H.W., Lu C.M., Mauze S., Freeman S., Moreira A.L., Kaplan G., Coffman R.T. Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect. Immun. 2002, 70:6284-6293.
44. Noli C., Auxilia S.T. Treatment of canine Old World visceral leishmaniasis: a systematic review. Vet. Dermatol. 2005, 16:213-232.
45. Nylen S., Sacks D. Interleukin-10 and the pathogenesis of human visceral leishmaniasis. Trends Immunol. 2007, 28:378-384.
46. Palatnik-de-Sousa C.B. Vaccines for canine leishmaniasis. Front. Immunol. 2012, 3:69.
47. Pinelli E., Killick-Kendrick R., Wagenaar J., Bernadina W., del Real G., Ruitenberg J. Cellular and humoral immune responses in dogs experimentally and naturally infected with Leishmania infantum. Infect. Immun. 1994, 62:229-235.
48. Pinelli E., Van Der Kaaij S.Y., Splappendel R., Fragio C., Ruitemberg E.J., Bernadina W., Ruttem V.P.M.G. Detection of canine cytokine gene expression by reverse transcription-polymerase chain reaction. Vet. Immunol. Immunopathol. 1999, 69:121-126.
49. Quinnell R.J., Courtenay O., Shaw M.A., Day M.J., Garcez L.M., Dye C., Kaye P.M. Tissue cytokine responses in canine visceral leishmaniais. J. Infect. Dis. 2001, 183:1421-1424.
50. Rafati S., Nakhaee A., Taheri T., Taslimi Y., Darabi H., Eravani D., Sanos S., Kaye P., Taghikhani M., Jamshidi S., Rad M.A. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Vaccine 2005, 23(28):3716-3725.
51. Reiner S.L., Locksley R.M. The regulation of immunity to Leishmania major. Annu. Rev. Immunol. 1995, 13:151-177.
52. Reis A.B., Martins-Filho O.A., Teixeira-Carvalho A., Carvalho M.G., Mayrink W., Franca-Silva J.C., Giunchetti R.C., Mayirink W., Genaro O., Correa-Oliveira R., Martins-Filho O. Parasite density and impaired biochemical/hematological status are associated with severe clinical aspects of canine visceral leishmaniasis. Res. Vet. Sci. 2006, 81:68-75.
53. Reis A.B., Teixeira-Carvalho A., Vale A.M., Marques M.J., Giunchetti R.C., Mayrink W., Guerra L.L., Andrade R.A., Correa-Oliveira R., Martins-Filho O. Isotype patterns of immunoglobulins: hallmarks for clinical status and tissue parasite density in Brazilian dogs naturally infected by Leishmania (Leishmania) chagasi. Vet. Immunol. Immunopathol. 2006, 112:102-116.
54. Reis A.B., Giunchetti R.C., Carrilo E., Martins-Filho A.O., Moreno J. Immunity to Leishmania and the rational search for vaccines against canine leishmaniasis. Trends Parasitol. 2010, 26(7):341-349.
55. Roatt B.M., Aguiar-Soares R.D.O., Vitoriano-Souza J., Coura-Vital W., Braga S.L., Corrêa-Oliveira R., Martins-Filho O.A., Teixeira-Carvalho A., Lana M., Gontijo N.F., Marques M.J., Giunchetti R.C., Reis A.B. Performance of LBSap vaccine after intradermal challenge with L. infantum and saliva ofLu. longipalpis: immunogenicity and parasitological evaluation. PLoS ONE 2012, 10.1371/journal.pone.0049780.
56. Sisto M., Brandonisio O., Panaro M.A., Acquafredda A., Leogrande D., Fasanella A., Trotta T., Mitolo V.F. Inducible nitric oxide synthase expression in Leishmania-infected dog macrophages. Comp. Immunol. Microbiol. Infect. Dis. 2001, 24:247-254.
57. Squires K.E., Schreiber R.D., McElrath M.J., Rubin B.Y., Anderson S.L., Murray H.W. Experimental visceral leishmaniasis: role of endogenous IFN-gamma in host defense and tissue granulomatous response. J. Immunol. 1989, 143:4244-4249.
58. Strauss-Ayali D., Baneth G., Shora S., Okanoc F., Jaffe C.L. Interleukin-12 augments a Th1-type immune response manifested as lymphocyte proliferation and interferon gamma production in Leishmania infantum-infected dogs. Int. J. Parasitol. 2005, 35:63-73.
59. Tesh R.B. Control of zoonotic visceral leishmaniasis: is it time to change strategies?. Am. J. Trop. Med. Hyg. 1995, 52:287-292.
60. Trinchieri G. Interleukin-10 production by effector T cells: Th1 cells show self control. J. Exp. Med. 2007, 204:239-243.
61. Trinchieri G., Rengaraju M., D'Andrea A., Valiante N.M., Kubin M., Aste M., Chehime J. Producer cells of interleukin 12. Parasitol. Today 1993, 9(3):97.
62. Virmondes-Rodrigues J.R., Da Silva J.S., Campos-Neto A. Transforming growth factor beta and immunosuppression in experimental visceral leishmaniasis. Infect. Immun. 1998, 66:1233-1236.
63. Vitoriano-Souza J., Reis A.B., Moreira N.D., Giunchetti R.C., Correa-Oliveira R., Carneiro C.M. Kinetics of cell migration to the dermis and hypodermis in dogs vaccinated with antigenic compounds of Leishmania braziliensis plus saponin. Vaccine 2008, 26:3922-3931.